Podcasts about polarityte

On this week's Tech Nation, Moira speaks with Dr. Robert Ang, the President & CEO of Vor Biopharma, about its approach to Acute Myeloid Leukemia, also known as AML. Then, Dr. Nik Sopko, the chief scientific officer of PolarityTE, talked about their design for wound healing. Their first treatment candidate is diabetic foot ulcers, and Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

Richard Hague is the CEO and President of PolarityTE, creating a paste-like substance containing multicellular skin segments that can be spread on the patient's wound bed and engrafts into the wound. This stimulates healing from the inside out with wounds created by diabetic foot ulcer and venous leg ulcer. Richard elaborates, "We're very excited about our SkinTE platform. It's a very unique and novel approach for treating wounds. The goal here is to use the patient's own cells so that there's no risk of rejection of any kind, no introduction of anything foreign to the body." "The first thing that happens is a physician takes a very small, full thickness harvest from the patient's body, usually somewhere in the proximal calf area. So this is healthy tissue. It's a small harvest that's easily stitched up and closed. And that tissue is sent back to our facility in Salt Lake City. We have a proprietary process for processing that skin that allows us to utilize all aspects of that harvest. So we're using all layers of the cells and all the extracellular material that's in that full thickness skin." @PolarityTE #PolarityTE #SkinTE #DiabeticFootUlcers #Diabetes #PressureUlcers PolarityTE.com Download the transcript here

Richard Hague is the CEO and President of PolarityTE, creating a paste-like substance containing multicellular skin segments that can be spread on the patient's wound bed and engrafts into the wound. This stimulates healing from the inside out with wounds created by diabetic foot ulcer and venous leg ulcer. Richard elaborates, "We're very excited about our SkinTE platform. It's a very unique and novel approach for treating wounds. The goal here is to use the patient's own cells so that there's no risk of rejection of any kind, no introduction of anything foreign to the body." "The first thing that happens is a physician takes a very small, full thickness harvest from the patient's body, usually somewhere in the proximal calf area. So this is healthy tissue. It's a small harvest that's easily stitched up and closed. And that tissue is sent back to our facility in Salt Lake City. We have a proprietary process for processing that skin that allows us to utilize all aspects of that harvest. So we're using all layers of the cells and all the extracellular material that's in that full thickness skin." @PolarityTE #PolarityTE #SkinTE #DiabeticFootUlcers #Diabetes #PressureUlcers PolarityTE.com Listen to the podcast here

On this week's Tech Nation, Moira speaks with Dr. Robert Ang, the President & CEO of Vor Biopharma about its approach to Acute Myeloid Leukemia, also known as AML. Then Dr. Nik Sopko, the Chief Scientific Officer of PolarityTE talks about their design for wound healing. Their first treatment candidate is diabetic foot ulcers. And Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

On this week's Tech Nation, Moira speaks with Dr. Robert Ang, the President & CEO of Vor Biopharma about its approach to Acute Myeloid Leukemia, also known as AML. Then Dr. Nik Sopko, the Chief Scientific Officer of PolarityTE talks about their design for wound healing. Their first treatment candidate is diabetic foot ulcers. And Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

The process of regenerating damaged skin tissue has been happening naturally in humans for millennia, and as medical experts continue to develop faster and more effective regenerative medicines, this process continues to evolve and progress.  Dr. Ryan Mathis, Chief Medical Officer at PolarityTE and former plastic surgery resident at Georgetown University, has been on the frontlines of skin regeneration research. PolarityTE is pioneering a new tissue engineering method called SkinTE, and Dr. Mathis clues us in on how this method functions.  Listen now as Dr. Mathis discusses: How SkinTE can take cells from a patient to regenerate tissue for treatment of wounds. How diabetic foot ulcers worsen, and the role of skin regeneration in treating them. The different ways the body heals wounds. Find more information about Dr. Mathis's research and SkinTE at Polarityte.com. This episode was brought to you by FeelGood Hemp, for 33% off your first purchase, use the code GENIUS33 at checkout! Episode also available on Apple Podcast: http://apple.co/30PvU9C

Dr. Ryan Mathis, MD, Vice President of Commercial Strategy at PolarityTE discusses SkinTE™ an innovative alternative for the treatment of chronic wounds, like diabetic foot ulcers (DFUs). He talks about the science behind SkinTE™, how it's made of a patient's own full-thickness skin, which retains the endogenous regenerative cellular populations found throughout his/her skin within multicellular segments. He also shares information from real-world studies of difficult to treat wounds. SkinTE™ is on track for IND submission in the second half of 2021. #woundcareskin #regenerativemedicine #tissueengineering Ryan K. Mathis, MD. Ryan earned his undergraduate and medical degrees at Penn State University before joining the Medstar Georgetown University Plastic Surgery Department as a resident. While at Georgetown, Ryan took leadership roles on the House Staff Quality Council and the Graduate Medical Education Council; he also received numerous awards from his peers and colleagues for distinguished clinical performance and for medical education. Ryan has published multiple papers and presented on various clinical and basic science research topics in the fields of plastic surgery, cardiac surgery, and wound care. Ryan left residency in 2017 to join PolarityTE and help translate the technology. Since joining Ryan has led multiple departments in the organization including Clinical Operations, Medical Affairs, Marketing, Market Access, Business development and Commercial. Ryan also serves as an advisor for numerous early-stage biotechnology and diagnostic companies and a visiting Professor for the Biotechnology Program at Georgetown University.

Dr. Ryan Mathis is the Vice President of Commercial Strategy at PolarityTE, focusing on bringing regenerative medicine into clinical practice, particularly for treating diabetic foot ulcers and other forms of complex wounds. Ryan says, "So, we're trying to solve this problem by developing SkinTE, which is revolutionizing the science for these hard-to-close wounds. The product itself is an autologous product, meaning we use a patient's own skin to produce the product.  Within your skin, there are regenerative cellular populations themselves, most highly focused around your hair follicles, that have the ability to heal wounds. And so, when you normally get a cut, those cells mobilize and move up towards the surface of the skin and heal the wounds." Listen to the podcast or read the transcript to find out how this innovative treatment creates a paste that gives the wound the ability to heal from the inside out. @PolarityTE #regenerativemedicine #tissueengineering #skin #woundcare #woundhealing #complexwound #diabetic #diabeticfootulcers PolarityTE.com Download the transcript here

Dr. Ryan Mathis is the Vice President of Commercial Strategy at PolarityTE, focusing on bringing regenerative medicine into clinical practice, particularly for treating diabetic foot ulcers and other forms of complex wounds. Ryan says, "So, we're trying to solve this problem by developing SkinTE, which is revolutionizing the science for these hard-to-close wounds. The product itself is an autologous product, meaning we use a patient's own skin to produce the product.  Within your skin, there are regenerative cellular populations themselves, most highly focused around your hair follicles, that have the ability to heal wounds. And so, when you normally get a cut, those cells mobilize and move up towards the surface of the skin and heal the wounds." Listen to the podcast or read the transcript to find out how this innovative treatment creates a paste that gives the wound the ability to heal from the inside out. @PolarityTE #regenerativemedicine #tissueengineering #skin #woundcare #woundhealing #complexwound #diabetic #diabeticfootulcers PolarityTE.com Listen to the podcast here

Dr. Denver Lough is President, Chief Executive Officer, and Chairman of PolarityTE, a biotech company developing methods for patients’ own cells to regenerate functionally-polarized tissues. Denver and the team at Polarity TE have developed novel methods to successfully induce regeneration across the full spectrum of tissue types including skin, muscle, and bone. They have accomplished this by understanding the environment, stimuli, and interactions needed for these tissues to orient, self-organize, and develop. With their technology, patients with a variety of diseases and injuries can regenerate fully functional tissues from their own cells. When he isn’t working at PolarityTE, Denver enjoys spending time with his wife and three young children. It is exciting to watch them learn and discover new things about the world, and it makes Denver appreciate all the incredible things in life that we sometimes overlook. Denver received his MD and PhD in Biochemistry and Molecular and Cell Biology from Georgetown University. He completed his residency in Plastic Surgery at Johns Hopkins University. Afterwards, Denver founded PolarityTE. In our interview Denver will tell us more about his life and science.

PolarityTE’s Denver Lough, MD, PhD, discusses the company’s new approach to treating burns with SkinTE (“autologous” tissue - meaning it comes from the patient being treated, significantly decreasing the chance for rejection by the immune system), the need for additional treatments in this area and case studies to highlight the efficacy of SkinTE. Listen to more health-related stories and research updates at www.hpr.fm

The Bottom Line (Original Air Date: November 6, 2018) – Denver Lough, MD, PhD is the Founder, CEO and President of PolarityTE. On the program, Dr. Lough talks to Doug about what led to his decision to leave medical school at Johns Hopkins University to form a regenerative medicine company that would later be known as PolarityTE.  […]

On Tech Nation Health, a radical new treatment to replace human skin following a serious burn. Dr. Denver Lough (“Low”), the President & CEO of PolarityTE, tells us how it works, and how a group of doctors left a hospital burn center to bring this new technology worldwide.

Moira speaks with Yale psychology professor John Bargh about “Before You Know It – The Unconscious Reasons We Do What We Do”. And on Tech Nation Health, a radical new treatment to replace human skin following a serious burn. Dr. Denver Lough (“Low”), the President & CEO of PolarityTE, tells us how it works, and how a group of doctors left a hospital burn center to bring this new technology worldwide.

Moira speaks with Yale psychology professor John Bargh about “Before You Know It – The Unconscious Reasons We Do What We Do”. And on Tech Nation Health, a radical new treatment to replace human skin following a serious burn. Dr. Denver Lough (“Low”), the President & CEO of PolarityTE, tells us how it works, and how a group of doctors left a hospital burn center to bring this new technology worldwide.

Breaking out on monthly and weekly charts. Just a question of when to enter! $cool $study

Denver Lough MD PhD is the President, CEO, CSO and Chairman of PolarityTE, a company looking to transform the regenerative medicine space. Denver shares his thoughts and insights on the most exciting and recent developments in regenerative medicine, including the work of his company PolarityTE, founded by a group of Johns Hopkins physician scientists. Denver discusses how PolarityTE is expanding the regenerative medicine space, building upon early foundational stem cell research, to be the first to produce fully functional, full thickness tissue across a number of tissue types.  We also talk about the FDA regulatory landscape and outstanding challenges in the field. @PolarityTE #PolarityTE #regenerativemedicine PolarityTE.com

On Tech Nation Health, a radical new treatment to replace human skin following a serious burn. Dr. Denver Lough (“Low”), the President & CEO of PolarityTE, tells us how it works, and how a group of doctors left a hospital burn centre to bring this new technology worldwide.

Straight from Benzinga newsdesk, hosts Brent Slava and Steve Krause bring you the market news and stocks to watch.Steve and Brent focus on:ATNX, we heard IBIO PRTK and STABToday's 5 Stock Ideas: AAPL PTE REGN SOPA PRTKApple (AAPL) - A Citi note on Apple Tuesday morning suggested regulatory risks for the company could create a near-term pullback in shares that should be used as a buying opportunity. Citi said it expects Apple will announce an added buyback between $80 billion and $90 billion and raise its dividend during the month of April.PolarityTE (PTE) - A penny stock play by famed Twitter account Zack Morris. On Monday evening, the account tweeted a $1 price target on PolarityTE. With shares trading around the $0.30 level Tuesday morning, the upside suggested by the Twitter account would total more than 200%.Regeneron (REGN) - A play on an upcoming FDA date. A panel of health experts is scheduled to rule on the company's Biologic License Application for its REGEN-CoV as a prophylactic treatment for COVID-19.Society Pass (SOPA) - One of the top three most-searched tickers on Benzinga Pro Tuesday morning. The stock is a low-float play with about 15 million shares in its float.Paratek Pharma (PRTK) - Shares spiked in late-day trade Monday following reports Russia used a chemical weapon in Ukraine. The stock was viewed as having exposure to this news as the company develops NUZYRA for post-exposure prophylaxis and the treatment of pulmonary anthrax.Hosts:Steve Krause Reach out to Steve at stevekrause@benzinga.comSr. Reporter Benzinga NewsdeskBrent Slava Reach out to Brent at brent@benzinga.comSr. Reporter, Head of Benzinga Newsdeskpro.benzinga.comFree 2-week trial, no credit card requiredUse coupon code YOUTUBE20 to get 20% offDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisionsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy